What Is GLP-1 Therapy Eligibility Screening?
GLP-1 therapy eligibility screening is an evaluation designed to determine whether a patient is an appropriate candidate for medications that enhance insulin function, reduce appetite, and support weight loss. These medications can significantly improve metabolic health, reduce liver fat, and lower the risk of diabetes and cardiovascular disease. Screening ensures safe, evidence-based prescribing and identifies patients who are most likely to benefit from treatment.
When Is GLP-1 Therapy Eligibility Screening Recommended?
Screening may be recommended for individuals who have one or more of the following:
- Obesity or elevated body mass index
- Type 2 diabetes, prediabetes, or insulin resistance
- Fatty liver disease (NAFLD/NASH)
- High blood pressure, high triglycerides, or low HDL
- Difficulty losing weight despite lifestyle changes
- Polycystic ovary syndrome (PCOS) or metabolic syndrome
- Cardiovascular risk factors such as sleep apnea
- Strong family history of metabolic or liver disease
How Is GLP-1 Therapy Eligibility Screening Performed?
Screening typically includes a medical history, physical examination, and laboratory testing to assess glucose control, insulin levels, kidney function, liver enzymes, and cardiovascular risk. Clinicians may also evaluate BMI, waist circumference, and previous responses to lifestyle interventions. The results help determine whether GLP-1 therapy is safe, medically indicated, and appropriate based on treatment goals.
What Are the Benefits of GLP-1 Therapy Eligibility Screening?
Key benefits include:
- Identifying safe candidates for medication-based weight loss
- Helping reduce liver fat, improve glucose control, and support cardiovascular health
- Personalized treatment planning based on medical risk factors
- Improved long-term outcomes for liver and metabolic disease